Skip to main content

Drug Interactions between semaglutide and turmeric

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

turmeric semaglutide

Applies to: turmeric and semaglutide

MONITOR: Coadministration of turmeric with antidiabetic drugs might potentiate the risk of hypoglycemia. Some small studies have shown that curcumin, the main component in turmeric, can reduce the blood levels of glucose and/or glycosylated hemoglobin (HbA1c) in diabetic patients. In a pharmacokinetic study involving eight type-2 diabetic patients, curcumin (475 mg daily) also increased glyburide (5 mg daily) blood levels by 12% at 2 hours after glyburide administration. The combination of glyburide and curcumin significantly decreased plasma glucose levels for up to 24 hours compared to glyburide alone. However, no patient experienced hypoglycemia.

MANAGEMENT: Caution is recommended if turmeric is coadministered with antidiabetic drugs. Blood glucose should be monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.

References (4)
  1. Neerati R, Devde R, Gangi AK (2014) "Evaluation of the effects of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus." Phytother Res, 28, p. 1796-1800
  2. Adibian M, Hodaei H, Nikpayam O, Sohrab G, Hekmatdoost A, Hedayati M (2019) "The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial." Phytother Res, 33, p. 1374-83
  3. Chuengsamarn S, Rattanamongkolgul s, Luechapudiporn R, Phisalaphong C, Jirawatnotai S (2012) "Curcumin extract for prevention of type 2 diabetes." Diabetes Care, 35, p. 2121-7
  4. Hodaei H, Adibian M, Nikpayam O, Hedayati M, Sohrab G (2019) "The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: a randomized, double-blind clinical trial." Diabet Metab Syndr, 11, e-collection 2019

Drug and food interactions

Moderate

semaglutide food

Applies to: semaglutide

ADJUST DOSING INTERVAL: Taking oral semaglutide with food, beverage, or other oral medications may alter semaglutide absorption and exposure. In a controlled study with healthy volunteers, limited or no measurable semaglutide exposure was observed in subjects that were fed 30 minutes prior to taking oral semaglutide, while all subjects that fasted overnight and 30 minutes after the oral semaglutide dose had measurable semaglutide exposure. Area under the curve (AUC) and semaglutide peak plasma concentration (Cmax) were approximately 40% greater in subjects that fasted compared to those who did not. AUC and Cmax were also increased with a post-dose fasting period greater than 30 minutes.

MANAGEMENT: It is recommended that oral semaglutide be taken 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces of plain water to ensure its efficacy. Fasting longer than 30 minutes after the oral semaglutide dose may lead to increased gastrointestinal side effects including nausea, vomiting, or diarrhea.

References (4)
  1. (2024) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Pharmaceuticals Inc
  2. (2024) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Canada Inc
  3. (2024) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Ltd
  4. Baekdal TA, Breitschaft A, Donsmark M, Maarbjerg SJ, Sondergaard FL, Borregaard J (2021) "Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation" Diabetes Ther, 12, p. 1915-27

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer